Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 6/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.43 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24330982 | 0.95 | SMN1; SMN2 (0.63) | SMN1; SMN2ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL29722013 | 0.87 | SMN1; SMN2 (0.60) | SMN1; SMN2ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL3021566 | 0.87 | SMN1; SMN2 (0.60) | SMN1; SMN2ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL28080097 | 0.83 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL3435026 | 0.82 | MEN1 (0.62) | SMN1; SMN2ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL19936511 | 0.81 | SMN1; SMN2 (0.62) | SMN1; SMN2ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL14006090 | 0.80 | ALDH1A1 (0.46) | SMN1; SMN2ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL21320757 | 0.80 | ALDH1A1 (0.46) | SMN1; SMN2ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL3031783 | 0.80 | ATM (0.51) | SMN1; SMN2ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL24329595 | 0.80 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1KDM4EHSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2173747-B1 | A REGIOSELECTIVE METAL CATALYZED SYNTHESIS OF ANNELATED BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI SA (FR) | 2011-12-21 | — | — | EP | claimed |
| US-20100216988-A1 | Regioselective metal catalyzed synthesis of annelated benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2010-08-26 | — | — | US | claimed |
| EP-2173747-A1 | A REGIOSELECTIVE METAL CATALYZED SYNTHESIS OF ANNELATED BENZIMIDAZOLES AND AZABENZIMIDAZOLES | Sanofi-Aventis (FR) | 2010-04-14 | — | — | EP | claimed |
| WO-2009000412-A1 | A REGIOSELECTIVE METAL CATALYZED SYNTHESIS OF ANNELATED BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI AVENTIS (FR) | 2008-12-31 | — | — | WO | claimed |
| WO-2022078403-A1 | SUBSTITUTED PYRIDONE COMPOUND AND APPLICATION | 江苏先声药业有限公司 | 2022-04-21 | — | — | WO | disclosed |
| EP-3201196-B1 | FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES | UCB Biopharma SRL (BE) | 2021-07-28 | — | — | EP | disclosed |
| EP-2173747-B1 | A REGIOSELECTIVE METAL CATALYZED SYNTHESIS OF ANNELATED BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI SA (FR) | 2011-12-21 | — | — | EP | disclosed |
| EP-2173747-B1 | A REGIOSELECTIVE METAL CATALYZED SYNTHESIS OF ANNELATED BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI SA (FR) | 2011-12-21 | — | — | EP | disclosed |
| US-20100216988-A1 | Regioselective metal catalyzed synthesis of annelated benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2010-08-26 | — | — | US | disclosed |
| US-20100216988-A1 | Regioselective metal catalyzed synthesis of annelated benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2010-08-26 | — | — | US | disclosed |
| US-20100216988-A1 | Regioselective metal catalyzed synthesis of annelated benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2010-08-26 | — | — | US | disclosed |
| EP-2173747-A1 | A REGIOSELECTIVE METAL CATALYZED SYNTHESIS OF ANNELATED BENZIMIDAZOLES AND AZABENZIMIDAZOLES | Sanofi-Aventis (FR) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009000412-A1 | A REGIOSELECTIVE METAL CATALYZED SYNTHESIS OF ANNELATED BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI AVENTIS (FR) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009000412-A1 | A REGIOSELECTIVE METAL CATALYZED SYNTHESIS OF ANNELATED BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI AVENTIS (FR) | 2008-12-31 | — | — | WO | disclosed |
| US-5246955-A | Pyrrolo(1,2-a)benzimidazole 5,8-diones, antitumor | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1993-09-21 | — | — | US | disclosed |
| US-5015742-A | Antitumor agents | ARIZONA BOARD OF REGENTS (US) | 1991-05-14 | — | — | US | disclosed |
| US-4104194-A | 1,2-FUSED 5- OR 6-MEMBERED 1,3-DINITROGEN HETEROCYCLIC COMPOUNDS AS ANTICORROSION AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1978-08-01 | — | — | US | disclosed |
| US-4048174-A | ANTI-CORROSION AGENTS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216988-A1 | Regioselective metal catalyzed synthesis of annelated benzimidazoles and azabenzimidazoles | AZI2, NIT2, NISCH | SMN1; SMN2 2619/4885ALDH1A1 107/4885KDM4E 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.